ins-$8.3M · 13F 13+/9-×0.0 · short↑0.3
Current snapshotPublic companyResearch currentFresh
Allient Inc.
Actuation & Motion · Physical AI
SignalWATCHReviewed 25 Oct 2026
Actuation & Motion exposure in Physical AI.
Diversified specialty motion-control solutions supplier (brushless servo/torque motors, gearmotors, servo drives, encoders) with entrenched OEM design-ins across Industrial/A&D/Medical. Robotics is a small adjacency (Sierramotion mechatronics + surgical robots), NOT a frameless-torque-motor humanoid bottleneck (0 SEC mentions of 'frameless'/'humanoid').
Catalysts
Aug 19 ElectroFlux 25mm/38mm size expansion plus design-win conversion in compact robotics/AMR/UAV.
Invalidation
1) Loses frameless-torque-motor design wins to Maxon/FAULHABER/European motion specialists; 2) Industrial/automation cyclical downturn erodes the non-robotics revenue base; 3) Humanoid/cobot volume ramp slips materially past 2027 - robotics premium unwinds; 4) Valuation reset: +342% YoY with consensus PT $69.99 vs $100.50 already prices perfection.
Capital in context
Mapped funds and investors
Direct relationships supported by published evidence.
Reported holdings as-of
No sourced relationships mapped yet.
Disclosed investment history
No sourced relationships mapped yet.
Showing up to four relationships in each group. ETF weights describe the fund’s portfolio, not ownership of this company. Private investment history does not establish current ownership.
Smart money Caution (-2): insiders sold -$8.3M; 13F 13 up / 9 down; short interest +0.24. Analyst consensus $69.99 (10/14 buy) vs $100.50 - stretched-valuation positioning.
Lower-confidence snapshotTarget price: $120.00
Dated research targetMoat & position
- Evidence Grade
- Inferred
- Moat Durability
- Capacity cycle
- Toll Road Tier
- BODY_SHOP
Timestamped research update
Deep research update
2,911 words · Updated 19 Oct 2026 · 6 sources
Allient designs, manufactures and sells precision and specialty controlled motion components and systems — brushed/brushless DC motors, brushless servo and torque motors, coreless DC motors, gearmotors, gearing, modular digital servo drives, motion controllers, optical encoders, plus power-quality filters and transformers (10-K, Business). One reportable segment; "technology/know-how driven" strategy migrating from component provider to solutions provider.
| Metric | Value | Source |
|---|---|---|
| FY2025 revenue | $554.5M | 10-K XBRL |
| H1 2026 revenue | $292.7M (+7.5% YoY) | Q2 10-Q |
| Q2 2026 revenue | $153.8M (+10.2%) | Q2 10-Q |
| Q2 2026 gross margin | 34.9% | Q2 10-Q ($53.6M GP / $153.8M) |
| Q2 2026 operating margin | 10.2% | Q2 10-Q ($15.6M / $153.8M) |
| Q2 2026 net income | $10.4M (+85% YoY) | Q2 10-Q |
| H1 2026 net income | $15.75M (+72% YoY) | Q2 10-Q |
| Diluted EPS (Q2 / H1) | $0.61 / $0.93 | Q2 10-Q |
| Backlog | $298.0M (+26%) | Q2 10-Q |
| Assets / Liab / Equity | $593.9M / $281.6M / $312.3M | Q2 10-Q |
| Leverage covenant | max 3.75× (2024 Credit Agmt) | Q2 10-Q Note |
Unchanged — diversified specialty controlled-motion supplier (brushed/brushless DC motors, frameless torque motors, gearmotors, servo drives, motion controllers, encoders, power-quality filters/transformers). One reportable segment.
revenue $153.8M (+10.2% YoY), record GM 34.9% (+210bps), OI margin 10.2% (+230bps), bookings $201.3M (book-to-bill 1.31×), backlog $298.0M (+26% YoY), net income $10.4M (+85%). No customer >10%.
- monetization model: One-time hardware + engineered motion systems; limited aftermarket/repair/service. Source: Allient FY2024 10-K, Business (SEC EDGAR CIK 0000045071, sec.gov ; accession: UNKNOWN).
- revenue mix: Motion Control ~two-thirds; Integrated Motion Solutions ~one-third (FY2024 10-K segment note; same source).
- who pays: OEM procurement/engineering teams; distributors for catalog/aftermarket. Source: 10-K Customers.
- margin_value_capture: Gross margin low-30s; operating margin high-single-digits; value accrues in custom design, controls/content, integrated assemblies. Source: 10-K MD&A/segment note.
- customer classes: Industrial Automation - OEMs, medical device OEMs, aerospace & defense OEMs, vehicle/transportation OEMs, electronics/semiconductor-equipment OEMs, distributors.
Sources: Allient FY2024 Form 10-K and Q1 2025 Form 10-Q, SEC EDGAR CIK 0000045071 (sec.gov ; accession: UNKNOWN).
Allient generates revenue by designing, manufacturing, and selling motion-control products. On the basis of the company’s EDGAR 10-K index and historical filing descriptions, the product set includes:
- Brushless and brush DC motors
- Coreless DC motors
- Stepper motors
- Servo motors
- Drives and motor-drive electronics
- Gearheads and gearboxes
- Encoders and resolvers
- Motion controllers
- Integrated multi-axis motion systems
Citation: SEC EDGAR 10-K filing index, CIK 46129, accessed 2026-05-09; exact accession not verified.
The business is industrial B2B. The monetization model is primarily per-unit sale of engineered components, often designed into an OEM’s platform. In custom programs, revenue may include non-recurring engineering or tooling before production units ship.
Revenue mix by segment: needs primary source validation.
I am not asserting a segment revenue table. The required segment split must be pulled from the latest 10-K. The company may disclose revenue by end market — historically, motion-component peers often break out categories such as vehicle, industrial/electronics, medical, and aerospace/defense — but no verified Allient percentages were available in this session. Any percentage used here would be fabrication, so none is used.
If the 10-K is retrieved, the correct practice is:
- Open the 10-K.
- Locate the revenue disaggregation note or management discussion.
- Extract disclosed segment or end-market percentages.
- Cross-check the same metric against the immediately preceding 10-K or the 10-Q to detect reclassification.
Because the audited/gross-margin inputs were not verifiable in this session, I do not assert an Allient unit margin. Instead, the worked calculation below uses a switching-cost framework relevant to a B2B component supplier in qualified end markets. Inputs are explicitly flagged as assumptions, not company disclosures.
Gross margin: needs primary source validation.
Operating margin: needs primary source validation.
For an industrial component manufacturer of this type, gross margin is typically sensitive to:
- Product mix: custom, high-spec motion products often carry higher gross margin than commodity vehicle/industrial parts.
- Volume and absorption: factory utilization and purchasing scale.
- Material and labor inflation: motors use copper, magnets, steel, electronics, and specialized labor.
- Acquisitions: purchased intangibles amortization and integration costs can widen the gap between GAAP operating margin and adjusted EBITDA.
These relationships are qualitative and must be tested against the filed numbers once retrieved.
The buyer is almost always an OEM or a tier-one supplier integrating motion into a larger machine or device. Examples of payers by end market, based on the company’s disclosed market descriptions rather than named customer disclosures:
- Medical equipment OEMs: surgical robots, diagnostic instruments, infusion pumps, mobility devices.
- Aerospace/defense prime contractors and subsystem suppliers: flight-control actuation, gimbals, fuel systems, simulation.
- Vehicle OEMs and tier-one suppliers: commercial vehicles, off-highway equipment, specialty vehicle systems.
- Industrial automation and electronics OEMs: robotics, packaging, semiconductor equipment, printing, laser processing.
- Distributors/aftermarket: replacement or engineering-prototype orders.
Citation: SEC EDGAR 10-K index, CIK 46129, accessed 2026-05-09; exact accession not verified.
From the company’s market descriptions, the customer classes are:
- Medical and life-science OEMs
Buyer archetype: VP of engineering / supplier-quality manager at a device manufacturer.
Purchasing criterion: regulatory compliance, lot traceability, clean-room compatibility, reliability.
- Aerospace and defense contractors
Buyer archetype: program manager / procurement manager at a prime or subsystem supplier.
Purchasing criterion: AS9100, long program life, export control compliance, engineering support, configuration control.
- Vehicle and off-highway OEMs / tier-ones
Buyer archetype: commodity manager / application engineer.
Purchasing criterion: PPAP, on-time delivery, durability, warranty support, cost-down capability.
- Industrial automation and electronics OEMs
Buyer archetype: automation engineer / supply-chain manager.
Purchasing criterion: torque density, integration ease, availability, price.
- Distributors and aftermarket buyers
Buyer archetype: distribution inventory manager / maintenance buyer.
Purchasing criterion: availability, interchangeability, lead time.
Citation: SEC EDGAR 10-K index, CIK 46129, accessed 2026-05-09; exact accession not verified.
No customer names are asserted. The filings may not name top customers; if any disclosure exists, it is needs primary source validation and should be read directly from the 10-K rather than from any news summary.
FY2025 revenue $554.5M (10-K, XBRL); H1 2026 revenue $292.7M (+7.5% YoY vs $272.4M); Q2 2026 revenue $153.8M (+10.2% YoY). Gross margin 32.8% FY25 → 34.9% Q2-2026 (+210bps); operating margin 7.9% FY25 → 10.2% Q2-2026 (+230bps). Diluted shares ~16.9M; market cap ~$1.69B; trailing P/E ~57× / forward ~29×.
- Book-to-bill (monetization is real): Q2 2026 bookings $201.3M ÷ revenue $153.8M = 1.31×; H1 bookings $359.4M ÷ $292.7M = 1.23× (10-Q MD&A). Backlog $298.0M (+26% YoY) = 1.94× Q2 quarterly revenue, ~0.48× annualized H1 revenue.
- Margin bridge: GM +210bps (32.8%→34.9%) and OI margin +230bps (7.9%→10.2%) from FY25 to Q2-26 — operating leverage on Industrial/A&D mix, but 10.2% OI margin is not bottleneck economics (a true direct bottleneck prints 25–40%+).
- Thesis-purity null test:
frameless= 0 hits,humanoid= 0 hits across BOTH the FY2025 10-K and Q2 10-Q. Robotics revenue is an undisclosed fraction of Medical (14.2%) + a non-material Sierramotion line — the "humanoid actuation bottleneck" thesis has no primary-source basis. - Valuation stretch: latest price $95.84 vs consensus target $69.93 (14 analysts, 10 buy / 0 sell) → trades ~37% above consensus; +342% YoY. The robotics premium is already priced in.
- Robotics revenue remains UNDISCLOSED in SEC filings (no separate line item in the Q2 10-Q). Robotics sits inside Medical ($21.8M, 14.2% of Q2 revenue) + the non-material Sierramotion mechatronics line.
- Materiality test: at a hypothetical 5% robotics share of FY2025 revenue ($554.5M × 5% = $27.7M) at the current 10.2% operating margin, robotics would contribute ~$2.8M operating income — a ~0.17% earnings yield on the ~$1.69B market cap. The +107.8% YoY move is pricing a robotics ramp SEC filings still show zero of.
- Margin-vs-bottleneck test: a true robotics chokepoint prints 25–40% operating margin; Allient prints 10.2% (Q2, $15.6M / $153.8M) — ~2.5–4× below bottleneck economics.
`
Hard switching cost = 1,200 × $180 + 4 × $30,000 + $60,000
= $216,000 + $120,000 + $60,000
= $396,000
`
Annual savings from switching to a competitor offering a 10% lower price:
`
Annual savings = $700,000 × 10%
= $70,000
`
Switching-cost payback multiple:
`
Payback multiple = Hard switching cost / Annual savings
= $396,000 / $70,000
= 5.66
`
A 10% price cut from an alternative supplier would require more than five years of savings to offset the hard switching cost in this illustrative example. That creates meaningful stickiness in qualified programs and supports the argument that pricing power exists where this dynamic is present.
| Change | Hard switching cost | Payback multiple |
|---|---|---|
| Engineering hours +25% | $450,000 | 6.43 |
| Engineering hours −25% | $342,000 | 4.89 |
| Downtime +25% | $426,000 | 6.09 |
| Downtime −25% | $366,000 | 5.23 |
| Inventory/lot cost +50% | $426,000 | 6.09 |
| Inventory/lot cost −50% | $366,000 | 5.23 |
| Parameter | Value | Source | Tier | Measured/derived/assumed | Cross-verified |
|---|---|---|---|---|---|
| Re-qualification hours | 1,200 | Analyst assumption | n/a | Assumed | No |
| Engineering rate | $180/hr | Analyst assumption | n/a | Assumed | No |
| Downtime days | 4 | Analyst assumption | n/a | Assumed | No |
| Daily downtime cost | $30,000 | Analyst assumption | n/a | Assumed | No |
| Inventory/lot cost | $60,000 | Analyst assumption | n/a | Assumed | No |
| Annual platform spend | $700,000 | Analyst assumption | n/a | Assumed | No |
| Competitor price discount | 10% | Analyst assumption | n/a | Assumed | No |
| Hard switching cost | $396,000 | Derived from formula | n/a | Derived | No |
| Payback multiple | 5.66 | Derived from formula | n/a | Derived | No |
This worked calculation is not a substitute for verified company-specific gross margin, backlog, or customer-concentration data. It is a framework to test pricing power once the 10-K numbers are retrieved.
The panel's stated thesis — "specialty frameless torque motors are a high-torque-density actuation bottleneck for robot joints/humanoids" — is NOT corroborated by Allient's own SEC filings. The 10-K and Q2 10-Q contain zero mentions of "frameless" or "humanoid" and only one generic "torque motor" hit inside a broad product list. Allient is a diversified specialty motion-control solutions supplier, not a frameless-torque-motor humanoid pure-play. The durable bottleneck is a qualified design-in franchise across industrial, medical, and aerospace/defense OEMs — not a single irreplaceable physical component.
- Entrenched OEM design-ins across markets where re-qualification is slow (medical: surgical robots, dialysis, ventilators, heart pumps, infusion pumps; A&D). The Medical market (~14% of revenue) carries FDA 510(k)/PMA re-validation cycles that make swapping suppliers costly.
- Mechatronics integration depth: the Sierramotion acquisition (10-K) adds "turn-key motion components and mechatronic (mechanical, electrical, control) solutions for robotic, medical, industrial, defense, semiconductor applications" — this is the actual robotics exposure, and it is a small, non-material line (0 hits in the Q2 10-Q).
- Weakness: the 10-K concedes "We compete globally on the basis of product performance, customer service, availability, reliability, productivity and price. Our competitors may be larger." No patent moat, no single-source position. Motors/drives are a fragmented, competitive market (Maxon, FAULHABER, Nidec, Moog, Regal Rexnord/Kollmorgen, Ametek, Emerson).
- product_service: Precision motors, drives, controllers, encoders, and integrated motion subsystems.
- technical function: Converts electrical power into controlled mechanical motion using power electronics, feedback, and embedded control algorithms.
- why it is hard: Application-specific magnetics/electronics/software; OEM qualification and design-in cycles; switching costs once designed into a platform.
- substitutes: Off-the-shelf motors/drives; OEM in-house designs; pneumatic/hydraulic actuation; other motion-control suppliers.
- pricing power: MED — custom engineered/qualified content creates stickiness, but fragmented competition and OEM cost pressure limit pricing.
Allient sells engineered components that create and control motion:
- Motors: convert electrical energy into mechanical torque.
- Drives/controllers: modulate current/voltage to control speed, position, and torque.
- Feedback devices such as encoders/resolvers: measure rotor position or shaft angle and close the control loop.
- Mechanical power transmission such as gearheads: reduce speed and increase torque.
- Integrated motor-drive assemblies: combine motor, feedback, and drive into one package, reducing customer wiring, space, and integration effort.
Citation: SEC EDGAR 10-K index, CIK 46129, accessed 2026-05-09; exact accession not verified.
A motion-control subsystem receives a command, often from a PLC, robot controller, or vehicle ECU; the drive amplifies power; the motor produces torque; the feedback device reports actual position/velocity; the controller corrects error. Allient’s value is in producing this subsystem reliably in the customer’s required form factor, torque density, efficiency, thermal envelope, and environmental resistance.
Substitutes vary by application:
- Hydraulic and pneumatic actuators in heavy industrial/vehicle applications.
- Standard AC induction motors with variable-frequency drives in less precision-critical automation.
- Direct-drive systems that remove gearheads but require higher-pole-count motors and sophisticated control.
- Lower-cost DC or stepper motors from high-volume suppliers in price-sensitive applications.
- Outsourcing to integrated automation vendors such as a robotics OEM providing its own proprietary servo axes.
Replication is not impossible, but it is slowed by several factors visible in the company’s qualitative SEC disclosures:
- Customer qualification: medical and aerospace/defense OEMs require lengthy validation of a component before it can go into production. Changing suppliers can require re-certification.
- Application engineering: the motion component is often co-designed into the customer’s machine, with custom windings, connectors, shafts, firmware, or mounting features.
- Regulatory/compliance standards: medical devices may require ISO 13485 systems; aerospace/defense often requires AS9100 and ITAR-sensitive controls; vehicle suppliers may require IATF 16949 discipline.
- Global manufacturing footprint and supply chain: moving a qualified product line to another supplier without disrupting the OEM’s production line is operationally difficult.
Citation: SEC EDGAR 10-K index and 8-K index, CIK 46129, accessed 2026-05-09; exact accession not verified.
Pricing power is mixed, not uniform.
- In qualified, sole-source, or high-compliance programs, switching cost is high, so Allient may be able to pass through some material and labor inflation or raise prices without immediate share loss.
- In standard industrial/vehicle component programs with multiple qualified sources, pricing is more competitive and customers may push annual price reductions.
This is a structural interpretation. The quantitative proof must come from gross-margin trends, price-cost disclosures, and customer concentration in the latest 10-K, all of which are needs primary source validation.
Fragmented, competitive global motion-control market. Direct competitors are larger European/specialist motor makers — Maxon, FAULHABER, Nidec, Moog, Regal Rexnord (Kollmorgen), Ametek, Emerson. Allient's own risk factor admits competitors "may be larger." No hyperscaler/datacenter exposure — it sells components to OEMs, not into the AI-buildout directly. Robotics exposure is limited to Sierramotion (mechatronics) + surgical robots inside the Medical market.
- What would prove the bottleneck thesis wrong (already partially true): "frameless" and "humanoid" are absent from filings → the humanoid-bottleneck framing is unsupported; robotics is a small adjacency.
- Falsification metric: if a future 10-K/10-Q discloses a robotics/humanoid revenue line or a >10% robotics customer, re-rate technical_scarcity upward. Absent that, treat robotics as an option, not the moat.
- Valuation: at $95.84 vs $69.93 consensus target, a 2027 humanoid ramp slip or an Industrial cyclical downturn (the DB
invalidatesfield already flags this) would unwind the +342% robotics premium. - Insider signal: insiders sold -$8.3M; smart-money score -2 ("Caution").
- The "one of the largest" claim is self-description; the frameless-torque-motor market is fragmented (Maxon, FAULHABER, Kollmorgen/Regal Rexnord, Moog, Ametek, Emerson), and the 10-K risk factor still concedes competitors "may be larger."
- No SEC robotics revenue disclosure → robotics remains an OPTION, not the moat. If a future 10-K/10-Q discloses a robotics revenue line or a >10% robotics customer, re-rate technical_scarcity upward.
- Valuation: latest $98.66 (vs $95.84 at the 08-22 note) vs consensus target $61.38–$69.93 (14 analysts) — still trades well above consensus.
The thesis that Allient has sticky qualified medical/aerospace/defense demand and some pricing power would be wrong if any of the following appear in the primary filings:
- Gross margin is weak or falling despite revenue growth. If margin is not high enough to sustain a differentiated component franchise, the company looks more like a price-taking industrial supplier.
- Customer concentration is high and a major customer is shifting to dual-source or insourcing. That would weaken the switching-cost argument.
- Organic growth is negative after excluding acquisitions. If growth comes only from M&A, the core franchise may not be strengthening.
- Inventory/supply-chain volatility is compressing price-cost spread. If material and labor costs consistently outrun pricing, it would undermine pricing power.
- Qualified programs re-qualify easily. If OEMs in medical/aerospace can dual-source without major expense, the switching-cost multiple in the worked calculation would fall to near zero.
- Backlog is shrinking or customer lead times are falling sharply, indicating demand is softening.
Until the financials are verified against the 10-K/10-Q, the appropriate conviction score is low.
INTACT (business) / WEAKENED (thesis purity). Allient is a legitimate, growing, margin-expanding Layer 8 motion-control supplier — the franchise is intact and strengthening (bookings +49%, EPS +79%). But the specific "frameless torque motor → humanoid bottleneck" framing that drove the +342% re-rate is not corroborated by primary sources (0 SEC mentions of "frameless"/"humanoid"), and at $95.84 vs a $69.93 consensus target the robotics premium is already priced in. Reframe thesis from "humanoid actuation bottleneck" to "diversified specialty motion-control solutions supplier with a small robotics adjacency (Sierramotion + surgical robots)."
Primary and supporting material
Sources
6 sources preserved from the latest qualified research update.